Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12293937 | 0.87 | CA12 (0.32) | CA12CA9 | |
| SCHEMBL8282891 | 0.79 | PIK3CD (0.47) | PIK3CD | |
| SCHEMBL13851272 | 0.71 | BRD4 (0.41) | BRD4BRD2 | |
| SCHEMBL6274518 | 0.68 | CA12 (0.39) | CA12CA9 | |
| SCHEMBL13851041 | 0.67 | PIK3CD (0.34) | BRD4BRD2PIK3CD | |
| SCHEMBL8282888 | 0.65 | PIK3CD (0.41) | PIK3CD | |
| SCHEMBL7439838 | 0.65 | ELANE (0.32) | — | |
| SCHEMBL8613982 | 0.64 | CA12 (0.34) | CA12CA9 | |
| SCHEMBL719466 | 0.62 | F2 (0.48) | BRD4BRD2CA12CA9PIK3CD | |
| SCHEMBL26560680 | 0.61 | F2 (0.46) | BRD4BRD2CA12CA9PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7619094-B2 | Ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | SCHERING CORPORATION (US) | 2009-11-17 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070093430-A1 | Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | MERCK SHARP & DOHME CORP. | 2007-04-26 | — | — | US | disclosed |
| US-7173057-B2 | Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus | SCHERING CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093430-A1 | Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | PREP, PRSS1, P4HB | BRD4 1071/4885BRD2 2842/4885CA12 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.